PathAI

PathAI develops AI-powered pathology technology for anatomic pathology laboratories and biopharma companies. Its AISight platform is a cloud-native digital pathology image and case management system, with an AISight Dx version cleared by the FDA for primary diagnosis and CE-IVDR marked in Europe. PathAI also offers AI algorithm products for tissue and biomarker quantification, such as AIM-PDL1, AIM-HER and AIM-MASH, along with biopharma services for translational research, clinical development and companion diagnostics, supported by a network of more than 500 board-certified pathologists.

• AISight cloud-native digital pathology image and case management
• AISight Dx platform cleared by FDA (510(k)) for primary diagnosis and CE-IVDR marked
• AI algorithms for biomarker quantification (e.g. AIM-PDL1, AIM-HER, AIM-ER/PR, AIM-Ki67)
• AIM-MASH, FDA-qualified AI tool for MASH clinical trials
• Biopharma services: translational research, clinical development, companion diagnostics